Stem Cell Traders Flock to Geron

• By the tickerspy.com Staff
• On 11:47 am EDT, Friday October 30, 2009

Investors cheered results from Geron (NASDAQ: GERN - News) on Friday, giving selected stem cell stocks a much needed boost.

A narrowed loss in the third quarter is helping Menlo Park, California-based Geron Corporation move closer to positive territory for the week, a period in which some of its peers have fallen by as much as -25%. Geron lost -$15.2 million in the three months ended September 30, better than the -$17.2 million in the same period last year. Meanwhile, total revenues were up by 35% year-over-year to $494,000.

As a whole, the Stem Cell Stocks Index is ahead by 2.4% today while the broader markets pare yesterday's 200 point Dow rally. The sector is still trailing the S&P 500 by more than -20% over the last month.

Aastrom Biosciences (NASDAQ: ASTM - News) and StemCells (NASDAQ: STEM - News) are both ahead by more than 4% in today's session, though they are also all down by more than -4% over the last week.

Meanwhile, Neuralstem (AMEX: CUR - News), Cytori Therapeutics (NASDAQ: CYTX - News), and Osiris Therapeutics (NASDAQ: OSIR - News) are extending weekly losses.

Sorting the Stem Cell Stocks Index's portfolio by '% of Daily' shows that Geron is the only stock in the Index experiencing abnormally high volume. Meanwhile, Opexa's (NASDAQ: OPXA - News) morning swing is on less than 100,000 shares traded - a mere 20% of its average for the time of this writing.

As of this writing, the Stem Cell Stocks Index is one of the five worst-performing tickerspy Indexes over the last month, down by -20%.

Fun and informative, tickerspy.com is a free investing website where you can track multiple stock portfolios and compare against 250 proprietary Indexes tracking themes from stem cells to green energy to precious metals. Best of all, tickerspy.com lets you spy on the portfolios of nearly 3,000 Wall Street institutions and hedge funds and see graphs of their performance. Try tickerspy.com today and find out how you stack up against investing legends like Warren Buffett!

Buzz up!